SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway

Yusuke Takagi, Kazuyuki Shimada, Satoko Shimada, Akihiko Sakamoto, Tomoki Naoe, Shigeo Nakamura, Fumihiko Hayakawa, Akihiro Tomita, Hitoshi Kiyoi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although the clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one-third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initial treatment in order to select optimal therapies. Here, we investigated the clinical and biological significance of SPIB, an Ets family transcription factor linked to lymphomagenesis, in DLBCL. We classified 134 DLBCL patients into SPIB negative (n = 108) or SPIB positive (n = 26) groups by immunohistochemical staining. SPIB positive patients had a significantly worse treatment response and poor prognosis compared with SPIB negative patients. Multivariate analysis for patient survival indicated that SPIB expression was an independent poor prognostic factor for both progression free survival (PFS) and overall survival (OS) (PFS, hazard ratio [HR] 2.65, 95% confidence interval [CI] 1.31–5.33, P = 0.006; OS, HR 3.56, 95% CI 1.43–8.91, P = 0.007). Subsequent analyses of the roles of SPIB expression in DLBCL pathogenesis revealed that SPIB expression in lymphoma cells resulted in resistance to the BH3-mimetic ABT-263 and contributed to apoptosis resistance via the PI3K-AKT pathway. The inhibition of AKT phosphorylation re-sensitized SPIB expressing lymphoma cells to ABT-263-induced cell death. Together, our data indicate that SPIB expression is a clinically novel poor prognostic factor in DLBCL that contributes to treatment resistance, at least in part, through an anti-apoptotic mechanism.

Original languageEnglish
Pages (from-to)1270-1280
Number of pages11
JournalCancer Science
Volume107
Issue number9
DOIs
Publication statusPublished - 01-09-2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Phosphatidylinositol 3-Kinases
Apoptosis
Disease-Free Survival
Survival
Lymphoma
Proto-Oncogene Proteins c-ets
Confidence Intervals
Therapeutics
Cell Death
Multivariate Analysis
Phosphorylation
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takagi, Y., Shimada, K., Shimada, S., Sakamoto, A., Naoe, T., Nakamura, S., ... Kiyoi, H. (2016). SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Science, 107(9), 1270-1280. https://doi.org/10.1111/cas.13001
Takagi, Yusuke ; Shimada, Kazuyuki ; Shimada, Satoko ; Sakamoto, Akihiko ; Naoe, Tomoki ; Nakamura, Shigeo ; Hayakawa, Fumihiko ; Tomita, Akihiro ; Kiyoi, Hitoshi. / SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. In: Cancer Science. 2016 ; Vol. 107, No. 9. pp. 1270-1280.
@article{8c9d61fad6254a1fb274a8fe15a5fc70,
title = "SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway",
abstract = "Although the clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one-third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initial treatment in order to select optimal therapies. Here, we investigated the clinical and biological significance of SPIB, an Ets family transcription factor linked to lymphomagenesis, in DLBCL. We classified 134 DLBCL patients into SPIB negative (n = 108) or SPIB positive (n = 26) groups by immunohistochemical staining. SPIB positive patients had a significantly worse treatment response and poor prognosis compared with SPIB negative patients. Multivariate analysis for patient survival indicated that SPIB expression was an independent poor prognostic factor for both progression free survival (PFS) and overall survival (OS) (PFS, hazard ratio [HR] 2.65, 95{\%} confidence interval [CI] 1.31–5.33, P = 0.006; OS, HR 3.56, 95{\%} CI 1.43–8.91, P = 0.007). Subsequent analyses of the roles of SPIB expression in DLBCL pathogenesis revealed that SPIB expression in lymphoma cells resulted in resistance to the BH3-mimetic ABT-263 and contributed to apoptosis resistance via the PI3K-AKT pathway. The inhibition of AKT phosphorylation re-sensitized SPIB expressing lymphoma cells to ABT-263-induced cell death. Together, our data indicate that SPIB expression is a clinically novel poor prognostic factor in DLBCL that contributes to treatment resistance, at least in part, through an anti-apoptotic mechanism.",
author = "Yusuke Takagi and Kazuyuki Shimada and Satoko Shimada and Akihiko Sakamoto and Tomoki Naoe and Shigeo Nakamura and Fumihiko Hayakawa and Akihiro Tomita and Hitoshi Kiyoi",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/cas.13001",
language = "English",
volume = "107",
pages = "1270--1280",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

Takagi, Y, Shimada, K, Shimada, S, Sakamoto, A, Naoe, T, Nakamura, S, Hayakawa, F, Tomita, A & Kiyoi, H 2016, 'SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway', Cancer Science, vol. 107, no. 9, pp. 1270-1280. https://doi.org/10.1111/cas.13001

SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. / Takagi, Yusuke; Shimada, Kazuyuki; Shimada, Satoko; Sakamoto, Akihiko; Naoe, Tomoki; Nakamura, Shigeo; Hayakawa, Fumihiko; Tomita, Akihiro; Kiyoi, Hitoshi.

In: Cancer Science, Vol. 107, No. 9, 01.09.2016, p. 1270-1280.

Research output: Contribution to journalArticle

TY - JOUR

T1 - SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway

AU - Takagi, Yusuke

AU - Shimada, Kazuyuki

AU - Shimada, Satoko

AU - Sakamoto, Akihiko

AU - Naoe, Tomoki

AU - Nakamura, Shigeo

AU - Hayakawa, Fumihiko

AU - Tomita, Akihiro

AU - Kiyoi, Hitoshi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Although the clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one-third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initial treatment in order to select optimal therapies. Here, we investigated the clinical and biological significance of SPIB, an Ets family transcription factor linked to lymphomagenesis, in DLBCL. We classified 134 DLBCL patients into SPIB negative (n = 108) or SPIB positive (n = 26) groups by immunohistochemical staining. SPIB positive patients had a significantly worse treatment response and poor prognosis compared with SPIB negative patients. Multivariate analysis for patient survival indicated that SPIB expression was an independent poor prognostic factor for both progression free survival (PFS) and overall survival (OS) (PFS, hazard ratio [HR] 2.65, 95% confidence interval [CI] 1.31–5.33, P = 0.006; OS, HR 3.56, 95% CI 1.43–8.91, P = 0.007). Subsequent analyses of the roles of SPIB expression in DLBCL pathogenesis revealed that SPIB expression in lymphoma cells resulted in resistance to the BH3-mimetic ABT-263 and contributed to apoptosis resistance via the PI3K-AKT pathway. The inhibition of AKT phosphorylation re-sensitized SPIB expressing lymphoma cells to ABT-263-induced cell death. Together, our data indicate that SPIB expression is a clinically novel poor prognostic factor in DLBCL that contributes to treatment resistance, at least in part, through an anti-apoptotic mechanism.

AB - Although the clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one-third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initial treatment in order to select optimal therapies. Here, we investigated the clinical and biological significance of SPIB, an Ets family transcription factor linked to lymphomagenesis, in DLBCL. We classified 134 DLBCL patients into SPIB negative (n = 108) or SPIB positive (n = 26) groups by immunohistochemical staining. SPIB positive patients had a significantly worse treatment response and poor prognosis compared with SPIB negative patients. Multivariate analysis for patient survival indicated that SPIB expression was an independent poor prognostic factor for both progression free survival (PFS) and overall survival (OS) (PFS, hazard ratio [HR] 2.65, 95% confidence interval [CI] 1.31–5.33, P = 0.006; OS, HR 3.56, 95% CI 1.43–8.91, P = 0.007). Subsequent analyses of the roles of SPIB expression in DLBCL pathogenesis revealed that SPIB expression in lymphoma cells resulted in resistance to the BH3-mimetic ABT-263 and contributed to apoptosis resistance via the PI3K-AKT pathway. The inhibition of AKT phosphorylation re-sensitized SPIB expressing lymphoma cells to ABT-263-induced cell death. Together, our data indicate that SPIB expression is a clinically novel poor prognostic factor in DLBCL that contributes to treatment resistance, at least in part, through an anti-apoptotic mechanism.

UR - http://www.scopus.com/inward/record.url?scp=84987620760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987620760&partnerID=8YFLogxK

U2 - 10.1111/cas.13001

DO - 10.1111/cas.13001

M3 - Article

C2 - 27348272

AN - SCOPUS:84987620760

VL - 107

SP - 1270

EP - 1280

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -